Table 1.
Baseline patient characteristics
| Recruited patients | Enrolled patients | ||
|---|---|---|---|
| Characteristics | Not treated with DEX implant on day 0 (N = 78) | Treated with DEX implant on day 0 (N = 392) | Analysis population (N = 375) |
| Age, mean (SD), years | 72.7 (11.4) | 70.4 (11.2) | 70.3 (11.2) |
| Range | 34–90 | 29–93 | 29–93 |
| Gender, n (%) | |||
| Male | 43 (55.1) | 214 (54.6) | 206 (54.9) |
| Female | 35 (44.9) | 178 (45.4) | 169 (45.1) |
| Diagnosis in study eye, n (%) | |||
| BRVO | 47 (60.3) | 211 (53.8) | 202 (53.9) |
| CRVO | 31 (39.7) | 181 (46.2) | 173 (46.1) |
| Time since onset of ME, mean (SD), months | 16.6 (26.3) | 11.3 (18.5) | 10.8 (18.1) |
| Median | 6.1 | 3.5 | 3.3 |
| BCVA in study eye, mean (SD), ETDRS letters | 47.0 (25.6) | 48.2 (21.4) | 47.6 (21.2) |
| Range | 0–85 | 0–85 | 0–85 |
| CRT in study eye, mean (SD), μm | 482 (204) | 551 (179) | 554 (180) |
| Ischemia status of the RVO, n (%) | |||
| Ischemic | 15 (19.7) | 33 (8.5) | 32 (8.6) |
| Non-ischemic | 45 (59.2) | 218 (56.0) | 209 (56.2) |
| Mixed | 16 (21.1) | 138 (35.5) | 131 (35.2) |
| Previous treatment for RVO, n (%)a | |||
| No (treatment-naïve) | 27 (34.6) | 153 (39.2) | 145 (38.9) |
| Yes (previously treated) | 51 (65.4) | 239 (61.0) | 228 (61.1) |
| Local ophthalmic treatment | 195 (52.3) | ||
| DEX implant | 23 (29.5) | 153 (39.2) | 149 (39.9) |
| Laser photocoagulation | 29 (37.2) | 116 (29.6) | 112 (30.0) |
| Triamcinolone acetonide | 6 (7.7) | 51 (13.0) | 49 (13.1) |
| Bevacizumab | 23 (29.5) | 37 (9.4) | 34 (9.1) |
| Ranibizumab | 20 (25.6) | 25 (6.4) | 24 (6.4) |
| Systemic treatmentb | 23 (29.5) | 114 (29.1) | 111 (29.8) |
| Lens status in the study eye, n (%)c | |||
| Phakic | 55 (70.5) | 284 (72.4) | 273 (72.8)d |
| Pseudophakic | 23 (29.5) | 107 (27.3) | 101 (26.9) |
| Ocular comorbidities in study eye, n (%) | |||
| Glaucoma | 25 (32.1) | 53 (13.5) | 52 (13.9) |
| Ocular hypertension | 26 (33.3) | 75 (19.1) | 73 (19.5) |
| Age-related macular degeneration | 3 (3.8) | 6 (1.5) | 5 (1.3) |
| Cataract | 18 (23.1) | 110 (28.1) | 108 (28.8) |
| IOP in study eye, mean (SD), mm Hg | 17.0 (7.1) | 14.6 (3.4) | 14.7 (3.0) |
BCVA Best-corrected visual acuity, BRVO Branch retinal vein occlusion, CRT Central retinal thickness, CRVO Central retinal vein occlusion, DEX implant Dexamethasone intravitreal implant 0.7 mg, ETDRS Early Treatment Diabetic Retinopathy Study, IOP Intraocular pressure, ME Macular edema, RVO Retinal vein occlusion, SD Standard deviation
aPercentages in analysis population based on N = 373 because two patients had missing data
bSystemic RVO treatments included aspirin, troxerutin, hemodilution, and other
cData missing for one eye
dAmong the phakic eyes, 165 were without cataract and 108 were with cataract